Thus, the dysregulation of AMPK and SIRT1 signaling in obesity not only disrupts metabolic homeostasis but also contributes to associated neurobehavioral and hepatic complications, highlighting their potential as therapeutic targets for metabolic and psychiatric disorders. This evidence concerns the gene PRKAA2 and obesity disorder.